A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

* Histologically or cytologically confirmed malignant solid tumor, and any of the following: \* Subjects with recurrent high grade serous ovarian cancer who completed or discontinued platinum based therapy; \* Subjects with BRCA-mutated breast cancer who have received prior chemotherapy with anthracycline and/or taxanes; \* Subjects with deleterious mutations of BRCA with advanced solid tumors who have received available standard therapies. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Life expectancy of greater than 12 weeks. * Adequate organ and marrow function· Measurable or non-measurable disease.

* Major surgery and/or radiation within (\<) 4 weeks prior to study enrollment. * Chemotherapy or hormone therapy within (\<) 4 weeks prior to study enrollment except for mitomycin C and nitrosoureas, in which case it is 6 weeks. * Any investigational agents within (\<) 4 weeks prior to study enrollment. * Any anti-cancer Chinese medicine/herbal remedies within 14 days prior to study enrollment. * Toxicities (with the exception of alopecia) from prior major surgery, radiation, or systemic chemotherapy have not recovered to less than grade 2.